Disclosures for "exPDite-2: A Phase Three, Randomized, Sham-controlled, Double-blind Trial to Evaluate Bemdaneprocel, a Midbrain Dopaminergic Neuron Progenitor Cell Therapy for Parkinson’s Disease"